Best Life Sciences Companies in Portland, United States

Developer of cannabis F1 hybrid seeds and natural THC products. The company empowers growers to produce high-quality cannabis cost-effectively. It offers elite, phenotypically-stable, fully-feminized true F1 hybrid seed lines. The company's seed-grown plants rival the uniformity of clonal varieties for harvest height, wet biomass, and total THC. It provides insights on mitigating HLVd risk with F1 hybrid production-ready seeds.

Funding rounds

• Dec 2025Series B$3M
• Dec 2025Series B$583.4K
• Oct 2024Series B$1.8M
• Nov 2023Series B$150K

Founders & team

Nishan KarassikChief Innovation Officer

Investors

Organigram, Merida Capital Partners, Accomplice, Entourage Effect Capital, Arcadian Capital, Artemis Growth Partners

Tech stack

Amazon Web ServicesCart FunctionalityCloudflareCloudflare Bot ManagementCore-JsExpress

Developing first-in-class biologics for life-threatening blood diseases with unmet needs. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel medicines for blood diseases. They are committed to bringing innovative therapies to patients. Their pipeline targets disease-modifying pathways with unique mechanisms of action. They are developing safe, paradigm-shifting drugs. Their research and development efforts focus on areas such as anticoagulation, thrombosis prevention, and inflammation reduction. They are working towards creating a positive social impact by addressing significant unmet medical needs in hematology. They are developing biologics and novel therapeutics.

Funding rounds

• Aug 2025Grant (prize money)$5.5M
• Feb 2025Grant (prize money)$3.8M
• Jun 2024Grant (prize money)$494K
• Oct 2023Seed—

Founders & team

Erik TuckerPresident & CEO

Investors

NYBC Ventures, HHS, OTRADI

Innovative diabetes management solutions through a single, integrated device. They are dedicated to simplifying diabetes management and improving health outcomes for individuals requiring insulin. Their core innovation, a single device integrating continuous glucose monitoring and insulin delivery, aims to reduce the burden of managing diabetes with multiple devices. This technology offers continuous glucose monitoring, potentially lowering the risk of complications and improving overall well-being. They address a critical need in diabetes care by offering a streamlined solution. This has a social impact by improving the lives of those with diabetes.

Funding rounds

• Oct 2025Series A$3.4M
• Mar 2025Series A$2.1M
• Sep 2023Series A$1.5M
• Sep 2019Grant (prize money)$1.8M

Founders & team

Robert S. CargillCEO & President

Investors

Cascadia Venture Forum, NIH, Helmsley Charitable Trust, HHS, Dorset Capital

Innovative women's health solutions for comfortable gynecological exams and procedures. This company is revolutionizing the gynecological exam experience with total solution products designed for patient comfort and clinician ease. They offer a range of modern speculums, including reusable and single-use options, along with accessories like tissue retraction sheaths and portable exam lights. Their products prioritize patient comfort with features like quiet operation, narrow designs, and temperature-neutral materials. They focus on innovation in women's health, offering solutions that improve clinician efficiency and enhance the overall patient experience. The company's products are available for purchase through their online store, with options to log in, view cart, and check out. They also provide resources like instructions for use, product brochures, and information on their story and mission. They are committed to empowering the GYN experience through design and innovation.

Funding rounds

• Feb 2025Series B$20M
• Jan 2020Series A$4.7M

Founders & team

Fahti KhosrowshahiFounder & CEO

Tech stack

Apple PayCart FunctionalityCloudflareCore-JsFont AwesomeGoogle Ads

Portable diagnostic devices empowering healthcare frontlines with affordable, accurate testing. They break traditional barriers with an innovative diagnostic system that expands the potential of diagnostics for important conditions, making accurate tests accessible to new locations and new populations. They design diagnostic technologies for the real world by listening to the needs of healthcare providers including those in some of the most remote and challenging settings. Their initial tests include sickle cell disease, beta thalassemia, and ferritin. They offer a miniaturized version of the gold standard test known as cellulose acetate electrophoresis. Results are displayed quickly and can be stored locally or transmitted to the Cloud for patient and disease tracking. They are focused on point-of-care diagnostics, portable diagnostics, and affordable healthcare solutions. They are working towards social impact by enabling early diagnosis and disease tracking.

Developer of dendritic cell (DC)-targeted complex vaccine combination immunotherapy for cancer. The platform technology, Autophagosome-enriched DRibble vaccine (DRibbles) is a first-in-class technology that combines more than 100 cancer targets. The lead product is DPV-001 (DRibble), a first-in-class dendritic cell (DC)-targeted complex vaccine combination immunotherapy for lung cancer. Also investigating DPV-001 for Breast Cancer, Advanced Prostate Cancer, Mesothelioma (Phase 1/2).

Provider of a therapeutic device for the treatment of vaginal atrophy and dryness. The company aims to enhance women's health, specifically giving postmenopausal women and breast cancer survivors non-hormonal treatment. The device is non-invasive and can be used at home, although the device is used based on a prescription from the doctor.

Funding rounds

• Sep 2024Grant (prize money)$1.5M
• Sep 2018Series A$4M
• Aug 2018Grant (prize money)$2.3M
• Apr 2017Grant (prize money)$275K

Founders & team

Holly RockweilerCo-Founder & CEO

Investors

OTRADI, Cascadia Venture Forum, America’s Seed Fund, One Ventures, HHS, Springboard Enterprises

Tech stack

Cart FunctionalitySquarespace CommerceSquarespaceStimulusPriority HintsGoogle Font Api

Developer of photosensitive dyes and instrument platform for fluorescence-guided cancer surgery. It offers solutions that combine proprietary photosensitive dyes and an instrument platform. This allows surgeons to visualize tumors more effectively, distinguish between healthy and malignant cells in solid tumors during fluorescence-guided surgery. The patented near-infrared nanoparticle becomes fluorescent as it encounters and accumulates in solid tumors. The proprietary software uses real-time images from the NIR camera system to guide the surgeon, ensuring more complete tumor resection.

Funding rounds

• May 2025Grant (prize money)$275K
• Jul 2024Grant (prize money)$275K
• Sep 2022Grant (prize money)$259.6K

Founders & team

August SickCEO

Investors

HHS, National Science Foundation

Bridging the gap between early-stage technology and marketplace success. The company helps technology leaders at universities and small biotech companies realize the full potential of their innovations. They provide expertise in navigating the scientific, regulatory, and funding landscapes necessary for bringing early-stage technologies to market. The team collaborates with partners across the United States, offering a comprehensive approach to technology development. Their focus is on maximizing the impact of groundbreaking technologies, ensuring they reach their intended audience and achieve commercial viability. They aim to accelerate the translation of research into real-world applications, fostering innovation and driving progress in the biotech industry.

Funding rounds

• Jun 2024Grant (prize money)$405.3K
• Sep 2019Grant (prize money)$268.6K
• Apr 2019Grant (prize money)$299.6K
• Aug 2017Grant (prize money)$299.2K

Founders & team

Jeff KingCEO

Investors

Sanderling Ventures, Pelion Venture Partners, Northwest Technology Ventures, Tenex Greenhouse Ventures, SBIR, NIST

Tech stack

WordpressMysqlPhpThemegrill SpaciousNginxJquery Migrate

PDX Pharmaceuticals is developing functionalized nanomaterials into therapeutics. The company focus is on developing novel nanomaterials from the hybrid of organic and inorganic materials for the treatment of cancer (breast, prostate, and pancreatic cancers), fibrosis, and hyperphosphatemia. Its drug pipeline includes PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ breast cancer; PDX-002 is a topical formulated nanoparticle platform for siRNA delivery to treat skin fibrosis; PDX-004 is an oral formulation of mesoporous silica modified with iron for the treatment of hyperphosphatemia.

Funding rounds

• Sep 2024Grant (prize money)$160.7K
• Jul 2023Grant (prize money)$1.3M
• Sep 2021Grant (prize money)$2.2M
• Sep 2021Grant (prize money)$2M

Founders & team

Wassana YantaseeCEO & President

Investors

HHS, OTRADI

Tech stack

WordpressMysqlPhpTwenty FourteenApache Http ServerJquery Migrate

Provider of imaging agents for surgery. It offers a nerve-targeting imaging agent that will highlight detailed anatomy in real-time to prevent surgical nerve damage and for precise surgery.

Developer of medical devices intended to offer a fracture reduction system. It offers a new minimally invasive fracture reduction system enabling surgeons to provide precise compression of fractures and fusions, allows for in situ implant contouring, and integrates with any implant system.

Funding rounds

• Dec 2024Seed$842.5K

Founders & team

Andy SeykoraCo-Founder & CEO